MinervaX Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $57.3M

  • Investors
  • 21

MinervaX General Information

Description

Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threatening infections caused by group B streptococcus. The company's vaccines specialize in the research and development of drugs that utilize a particular fusion protein that elicits protective immunity against a range of clinically relevant streptococci strains, enabling medical professionals to prevent newborn babies from contracting bacterial infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Nordre Fasanvej 215
  • 2200 Frederiksberg
  • Denmark
+45 39
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Nordre Fasanvej 215
  • 2200 Frederiksberg
  • Denmark
+45 39

MinervaX Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MinervaX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 11-Oct-2023 $57.3M Completed Clinical Trials - Phase 3
12. Later Stage VC 13-Dec-2022 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series B) 15-Dec-2020 Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private Completed Clinical Trials - Phase 1
9. Later Stage VC 21-Jan-2019 Completed Clinical Trials - Phase 1
8. Grant 19-Sep-2016 Completed Clinical Trials - Phase 1
7. Later Stage VC 15-Feb-2016 Completed Clinical Trials - Phase 1
6. Grant 28-Oct-2015 Completed Clinical Trials - Phase 1
5. Debt - General $4.79M Completed Clinical Trials - Phase 1
4. Later Stage VC 08-Jan-2014 $4.04M $4.79M Completed Clinical Trials - Phase 1
To view MinervaX’s complete valuation and funding history, request access »

MinervaX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares
C Shares 1,683,836 $0.142233 $3.98 $3.98 1x $3.98 6.72%
Series B 106,822 $0.142233 $5.69 $5.69 1x $5.69 0.43%
To view MinervaX’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MinervaX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of maternal vaccines designed for the prevention of adverse pregnancy outcomes and life-threatening infections
Drug Discovery
Frederiksberg, Denmark
50 As of 2024

Cantanhede, Portugal
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MinervaX Competitors (48)

One of MinervaX’s 48 competitors is Immunethep, a Venture Capital-Backed company based in Cantanhede, Portugal.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunethep Venture Capital-Backed Cantanhede, Portugal
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Virometix Venture Capital-Backed Schlieren, Switzerland
Anaveon Venture Capital-Backed Basel, Switzerland
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
You’re viewing 5 of 48 competitors. Get the full list »

MinervaX Patents

MinervaX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4837587-A1 Immunogenic fusion protein Pending 06-May-2025
WO-2026234068-A1 Immunogenic fusion protein Pending 06-May-2025
EP-4825390-A1 Method for producing a recombinant fusion protein Pending 17-Apr-2025
WO-2026220014-A1 Method for producing a recombinant fusion protein Pending 17-Apr-2025
EP-4825389-A1 Method for purifying a recombinant fusion protein Pending 17-Apr-2025 C07K14/315
To view MinervaX’s complete patent history, request access »

MinervaX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MinervaX Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
Kinled Holding Family Office
Novo Holdings Venture Capital Minority
OrbiMed Growth/Expansion Minority
Pureos Bioventures Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

MinervaX FAQs

  • When was MinervaX founded?

    MinervaX was founded in 2009.

  • Where is MinervaX headquartered?

    MinervaX is headquartered in Frederiksberg, Denmark.

  • What is the size of MinervaX?

    MinervaX has 50 total employees.

  • What industry is MinervaX in?

    MinervaX’s primary industry is Drug Discovery.

  • Is MinervaX a private or public company?

    MinervaX is a Private company.

  • What is the current valuation of MinervaX?

    The current valuation of MinervaX is .

  • What is MinervaX’s current revenue?

    The current revenue for MinervaX is .

  • How much funding has MinervaX raised over time?

    MinervaX has raised $203M.

  • Who are MinervaX’s investors?

    EQT Life Sciences, Kinled Holding, Novo Holdings, OrbiMed, and Pureos Bioventures are 5 of 21 investors who have invested in MinervaX.

  • Who are MinervaX’s competitors?

    Immunethep, Inovio Pharmaceuticals, Virometix, Anaveon, and Light Chain Bioscience are some of the 48 competitors of MinervaX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process